Richard T Penson

9PUBLICATIONS
93CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Apr 10, 2025
Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole/Abemaciclib in Endometrial Cancer.

Panagiotis A Konstantinopoulos, Mingyang Cai, Elizabeth K Lee

|Dec 12, 2024
Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results.

Giovanni Scambia, Ricardo Villalobos Valencia, Nicoletta Colombo

|Apr 18, 2024
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses.

Panagiotis A Konstantinopoulos, Su-Chun Cheng, Elizabeth K Lee

|Mar 13, 2024
PARP Inhibitors: Strategic Use and Optimal Management in Ovarian Cancer.

Nicholas Hirschl, Wildnese Leveque, Julia Granitto

|Mar 08, 2024
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors.

Ryan B Corcoran, Khanh T Do, Jeong E Kim

|Nov 08, 2023
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study.

Yvette Drew, Jae-Weon Kim, Richard T Penson

Pageof 2

Frequent Collaborators

4 joint publications

Joyce F Liu

4 joint publications

Ursula A Matulonis

3 joint publications

Panagiotis A Konstantinopoulos

3 joint publications

Elizabeth K Lee